Sofosbuvir

CAS 1190307-88-0

About the API

Systematic name (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate)
Trade name(s) Sovaldi
Technology Synthetic Organic Chemistry
Molecular Formula C22H29FN3O9P
Molecular Weight 529.45 g/mol
Physical properties white to off-white crystalline solid
Therapeutic category Antiviral
Available formulations Oral Solid
Regulations US DMF Flag US DMF

General Information

Sofosbuvir is an antiviral agent used in combination with other drugs to treat patients with chronic hepatitis C (CHC), a life threatening liver disease. CHC results from infection by the hepatitis C virus.

Sofosbuvir may be used in patients co-infected with HIV. In the past, treatment regimens for CHC often included injectables, and were frequently difficult to tolerate.

Sofosbuvir is orally administered in a pill that has relatively mild side effects and can be taken in combination with other orally administered drugs for CHC, obviating the need for injectables. Due to its mode of action, Sofosbuvir exhibits a high barrier to drug resistance development.

After receiving breakthrough therapy designation, Sofosbuvir was approved by the FDA in 2013 under the trade name Sovaldi.

It is produced through multi-step chemical synthesis.